For example, in ICIs, over 50% of cancer patients exhibit resistance to anti-PD1/PDL1 therapies due to the depletion of specific tumor-associated antigens, inadequate maturation of DCs, and insufficient activation and infiltration of CTLs [116, 117]. This evidence concerns the gene PDCD1 and neoplasm.